当前位置: X-MOL 学术N. Engl. J. Med. › 论文详情
A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants.
The New England Journal of Medicine ( IF 70.670 ) Pub Date : 2020-01-16 , DOI: 10.1056/nejmoa1907423
Sandra E Juul,Bryan A Comstock,Rajan Wadhawan,Dennis E Mayock,Sherry E Courtney,Tonya Robinson,Kaashif A Ahmad,Ellen Bendel-Stenzel,Mariana Baserga,Edmund F LaGamma,L Corbin Downey,Raghavendra Rao,Nancy Fahim,Andrea Lampland,Ivan D Frantz Iii,Janine Y Khan,Michael Weiss,Maureen M Gilmore,Robin K Ohls,Nishant Srinivasan,Jorge E Perez,Victor McKay,Phuong T Vu,Jean Lowe,Karl Kuban,T Michael O'Shea,Adam L Hartman,Patrick J Heagerty,

BACKGROUND High-dose erythropoietin has been shown to have a neuroprotective effect in preclinical models of neonatal brain injury, and phase 2 trials have suggested possible efficacy; however, the benefits and safety of this therapy in extremely preterm infants have not been established. METHODS In this multicenter, randomized, double-blind trial of high-dose erythropoietin, we assigned 941 infants who were born at 24 weeks 0 days to 27 weeks 6 days of gestation to receive erythropoietin or placebo within 24 hours after birth. Erythropoietin was administered intravenously at a dose of 1000 U per kilogram of body weight every 48 hours for a total of six doses, followed by a maintenance dose of 400 U per kilogram three times per week by subcutaneous injection through 32 completed weeks of postmenstrual age. Placebo was administered as intravenous saline followed by sham injections. The primary outcome was death or severe neurodevelopmental impairment at 22 to 26 months of postmenstrual age. Severe neurodevelopmental impairment was defined as severe cerebral palsy or a composite motor or composite cognitive score of less than 70 (which corresponds to 2 SD below the mean, with higher scores indicating better performance) on the Bayley Scales of Infant and Toddler Development, third edition. RESULTS A total of 741 infants were included in the per-protocol efficacy analysis: 376 received erythropoietin and 365 received placebo. There was no significant difference between the erythropoietin group and the placebo group in the incidence of death or severe neurodevelopmental impairment at 2 years of age (97 children [26%] vs. 94 children [26%]; relative risk, 1.03; 95% confidence interval, 0.81 to 1.32; P = 0.80). There were no significant differences between the groups in the rates of retinopathy of prematurity, intracranial hemorrhage, sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, or death or in the frequency of serious adverse events. CONCLUSIONS High-dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe neurodevelopmental impairment or death at 2 years of age. (Funded by the National Institute of Neurological Disorders and Stroke; PENUT ClinicalTrials.gov number, NCT01378273.).
更新日期:2020-01-16

 

全部期刊列表>>
向世界展示您的会议墙报和演示文稿
全球疫情及响应:BMC Medicine专题征稿
欢迎探索2019年最具下载量的化学论文
新版X-MOL期刊搜索和高级搜索功能介绍
化学材料学全球高引用
ACS材料视界
南方科技大学
x-mol收录
南方科技大学
自然科研论文编辑服务
西湖大学
中国科学院长春应化所于聪-4-8
武汉工程大学
课题组网站
X-MOL
深圳大学二维材料实验室张晗
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug